The capped upside and unlimited downside risk make MRNY unattractive unless Moderna's share price stabilizes and recovers ...

Yet today, the State is often told to step aside and let the private sector lead. This creates a paradox. Governments are blamed for not innovating, yet also told not to try. At the same time, many ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The new results helped boost Moderna’s stock by more than 4% in early trading June 30, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

The author says the action creates mistrust of the committee’s vaccine recommendations and further increases patients’ and ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

Everest Medicines unveils breakthroughs in AI+mRNA platform, reinforces global leadership in next-gen mRNA innovation: Hong Kong Monday, July 7, 2025, 10:00 Hrs [IST] Everest Medi ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...